In this article, we will look at the 11 Best Performing Long Term Stocks According to Analysts.

On September 19, Alli McCartney, Managing Director at UBS Private Wealth Management, and Philip Straehl, CIO Americas at Morningstar Wealth, joined CNBC to the rate cuts, market valuations and more.

Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000. The next day, all major indices hit new highs. She noted that this reflected mixed market reactions, with institutional investors waiting to see how falling employment and rate cuts would balance out. It was a cautious, interpretive phase following the Fed’s announcement.

On the other hand, Philip Straehl from Morningstar highlighted his bullish view on small-cap stocks, especially in the healthcare sector. He explained that small caps often depend on short-term borrowing and are more sensitive to Fed rate changes. Since expectations of rate cuts have increased, small caps have gained support as a result. He also noted that the small-cap value stocks still trade below their intrinsic value by 15% to 20%, so an easing cycle by the Fed could be a catalyst for their growth.

While talking about valuations, Alli McCartney noted that although the valuations are at nose-bleed levels, she pointed out that similar valuations in the past have led to gains when earnings and rate cuts aligned. She emphasized it is risky but sensible now to invest and not avoid the market, due to tailwinds including AI innovation, new stimulus, and a more aligned Fed policy. She advised investors to buy the dips when the market presents an opportunity.

With that, let’s take a look at the 11 best performing long term stocks according to analysts.

Our Methodology

To curate the list of 11 best performing long term stocks according to analysts, we used the Finviz Stock Screener, Seeking Alpha, CNN, and Insider Monkey’s Q2 2025 database as our sources. Using the screener we aggregated a list of long term stocks (5-year revenue growth rate of more than 10%) that have gained more than 30% year-to-date with analysts expecting more than 25% upside. Next, we cross-checked the revenue growth from Seeking Alpha and analyst upside from CNN. Lastly, we ranked the stocks in ascending order of the upside potential. We have also mentioned the hedge fund sentiment around each stock. Please note that the data was recorded on September 20, 2025.

​Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

11 Best Performing Long Term Stocks According to Analysts

11. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

5-year Revenue Growth Rate: 42.20%

Year-To-Date Performance: 85.71%

Number of Hedge Fund Holders: 58

Analysts Upside Potential: 26.03%

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with a price target of $70.

The analyst noted that his positive sentiment of the company is based on the company’s lead drug candidate Encaleret, which targets autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare condition with high unmet medical needs and often goes undiagnosed. He highlighted that Encaleret works differently from conventional treatments and acts as a negative allosteric modulator of the calcium-sensing receptor. This mechanism directly addresses the root cause of ADH1, which current therapies do not fully manage.

Moreover, the drug has shown strong results in a Phase 2 trial. Over 42 months, it helped normalize patients’ blood calcium, parathyroid hormone, and urine calcium levels. Importantly, Encaleret demonstrated a durable effect and a good safety profile over this long-term study.

In the United States alone there are around 12,000 patients affected by ADH1, presenting a sizable market opportunity for BridgeBio Pharma, Inc. (NASDAQ:BBIO).

BridgeBio Pharma, Inc. (NASDAQ:BBIO) discovers and develops medicines for genetic diseases. Its drug pipeline includes treatments for amyloidosis, achondroplasia, hypocalcemia, and muscular dystrophy.

10. Ascendis Pharma A/S (NASDAQ:ASND)

5-year Revenue Growth Rate: 125.53%

Year-To-Date Performance: 43.25%

Number of Hedge Fund Holders: 45

Analysts Upside Potential: 26.22%

Ascendis Pharma A/S (NASDAQ:ASND) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) with a price target of $230.

The firm named the company as one of its top picks for 2025. This comes after the company’s Yorvipath global launch in hypoparathyroidism showed strong initial results with further acceleration as payor coverage expands.

The analyst noted that the company’s strong execution is reflected in its impressive 54.5% revenue growth over the last twelve months, maintaining a robust gross margin of 84.88%. Moreover, Ahmad also believes that Yorvipath is well-positioned to capture market share as the only marketed product in its category, with competing pipeline products reportedly several years behind in development. The bank currently models $3.15 billion in peak sales for Yorvipath in HPT, which it calculates represents $147 per share in value.

Ascendis Pharma A/S (NASDAQ:ASND) is a Denmark-based pharmaceutical company that develops treatments for growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes.